Sonya Chapman is a PK/PD project leader at Eli Lilly and Company, currently leading strategies for pre-clinical and clinical development in oncology and neuroscience. Sonya's past experience includes roles as a research scientist and post-doctoral research fellow at Eli Lilly, where Sonya developed semi-mechanistic PK/PD models and investigated clinical predictions related to anti-tumor effects. Sonya began their career as an industrial trainee at Pfizer Pharmaceuticals, working on a translational PK/PD model for an anti-hypertensive agent. Sonya holds a PhD in Pharmacokinetics from The University of Manchester and an MChem in Chemistry from the University of York.
This person is not in any teams
This person is not in any offices